Barclays Lowers Illumina's Price Target to $77, Maintains 'Underweight' Rating
Apr 11, 2025 17:41
CST Updated
17:41
Illumina
Diagnostic Product Developer
Gelonghui April 11 | Barclays: Downgraded Illumina's target price from $100 to $77, maintaining an "Underweight" rating. (Gelonghui)